SCHEMBL13633497

SCHEMBL13633497

O=C(Nc1cn2ccc(Br)cc2n1)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 5/20 0.40
METTL3 Q86U44 2/20 0.39
HDAC4 P56524 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
PIK3C3 Q8NEB9 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
HDAC1 Q13547 1/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
RAB9A P51151 1/20 0.34
POLB P06746 1/20 0.34
CYP1A2 P05177 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633518 0.82 KDM4E (0.46) MAP3K5METTL3PIK3CAPIK3CDPIK3CB
SCHEMBL1302968 0.81 MAP3K5 (0.60) MAP3K5PIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL20798098 0.79 RAB9A (0.49) MAP3K5HDAC4L3MBTL1HDAC1KDM4E
SCHEMBL13633508 0.76 METTL3 (0.42) METTL3
SCHEMBL5935848 0.75 HRH4 (0.41) MAP3K5PIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL13633553 0.74 KMT2A (0.50) METTL3KDM4ENPC1ALDH1A1RAB9A
SCHEMBL25349894 0.74 RXFP1 (0.37) MAP3K5L3MBTL1PIK3CAKDM4ESMN1; SMN2
SCHEMBL3710368 0.74 PIK3CA (0.42) MAP3K5PIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL16439354 0.74 KDM4E (0.36) METTL3HDAC4L3MBTL1HDAC1KDM4E
SCHEMBL3705966 0.74 PIK3CD (0.45) PIK3CDPIK3CGKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015014283-A1 PROTEIN TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF 南京圣和药业股份有限公司 (CN) 2015-02-05 WO disclosed
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS PFIZER INC 2009-11-05 US disclosed
US-7563788-B2 Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents PFIZER INC. (US) 2009-07-21 US disclosed
US-20070191394-A1 Antibacterial agents WARNER-LAMBERT COMPANY LLC 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191394-A1 Antibacterial agents MRPL21, RPN2, FBL MAP3K5 3024/4885METTL3 4671/4885HDAC4 1950/4885
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS DPYD, TYMP, ITPA MAP3K5 1536/4885METTL3 4732/4885HDAC4 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.